Apogee Therapeutics (Apogee Therapeutics) Equity-to-Asset : 1.16 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Apogee Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $957.34 Mil. Apogee Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $823.66 Mil.

The historical rank and industry rank for Apogee Therapeutics's Equity-to-Asset or its related term are showing as below:

APGE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.87 Med: 1.05 Max: 1.25
Current: 1.16

During the past 2 years, the highest Equity to Asset Ratio of Apogee Therapeutics was 1.25. The lowest was 0.87. And the median was 1.05.

APGE's Equity-to-Asset is ranked better than
99.81% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs APGE: 1.16

Apogee Therapeutics Equity-to-Asset Historical Data

The historical data trend for Apogee Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics Equity-to-Asset Chart

Apogee Therapeutics Annual Data

Trend

Dec22

Dec23

Equity-to-Asset

0.93

1.25

Apogee Therapeutics Quarterly Data
	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial			0.92	0.87	1.18	1.25	1.16

Competitive Comparison of Apogee Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Apogee Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apogee Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Apogee Therapeutics's Equity-to-Asset falls into.

Apogee Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Apogee Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	503.354	/	401.404
	=

Apogee Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	957.342	/	823.659
	=

Apogee Therapeutics (NAS:APGE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Apogee Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Apogee Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Apogee Therapeutics (Apogee Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453

Website

https://www.apogeetherapeutics.com

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.

Executives

Mark C. Mckenna	director	400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Nimish P Shah	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jane Henderson	officer: Chief Financial Officer	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr	director	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Michael Thomas Henderson	director, officer: Chief Executive Officer	421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p.	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox	director	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener	director	3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Carl Dambkowski	officer: Chief Medical Officer	221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453